FDA Commissioner Outlines New Plan to Increase Biosimilars by Balancing Innovation and Competition

FDA Commissioner Scott Gottlieb, MD, has been outspoken about the critical need to reign in drug prices. Biosimilars are crucial for improving patient access to biologic drugs at an affordable cost. Biologics are now key in the treatment of cancer and autoimmune conditions. But cost remains an obstacle to access to drug therapy. As part of a larger shift to lower drug prices across the healthcare system, the FDA recently unveiled an 11-part action plan to boost the biosimilar industry as a way to lower drug costs through increased innovation and competition